



Universiteit
Leiden
The Netherlands

Facioscapulohumeral disease

Padberg, G.W.A.M.

Citation

Padberg, G. W. A. M. (1982, October 13). *Facioscapulohumeral disease*. Retrieved from <https://hdl.handle.net/1887/25818>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/25818>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/25818> holds various files of this Leiden University dissertation.

Author: Padberg, George Waltherus Adrianus Maria

Title: Facioscapulohumeral disease

Issue Date: 1982-10-13

Facioscapulohumeral disease

Proefschrift

TER VERKRIJGING VAN DE GRAAD VAN DOCTOR
IN DE GENEESKUNDE AAN DE RIJKSUNIVERSITEIT TE LEIDEN,
OP GEZAG VAN DE RECTOR MAGNIFICUS DR. A.A.H. KASSENAAR,
HOGLERAAR IN DE FACULTEIT DER GENEESKUNDE,
VOLGENS BESLUIT VAN HET COLLEGE VAN DEKANEN
TE VERDEDIGEN OP WOENSDAG 13 OKTOBER 1982
TE KLOKKE 15.15 UUR

door

GEORGE WALTHERUS ADRIANUS MARIA PADBERG
geboren te Wassenaar in 1948

Promotor : Prof. Dr. G.W. Bruyn
Co-promotor Dr. G.K. van Wijngaarden

Referenten : Prof. Dr. A.W. Eriksson
Prof. Dr. L.N. Went

ISBN 90 70176 71 8

© 1982 by the author.

No part of this publication may be translated or reproduced in any form, by print, photoprint, microfilm, or any other means, without the prior written permission from the author.

Printed in the Netherlands by Intercontinental Graphics, H.I. Ambacht.

Contents

INTRODUCTION		11
CHAPTER 1.	HISTORICAL NOTES	13
CHAPTER 2.	FACIOSCAPULOHUMERAL DISEASE:	
	REVIEW OF THE LITERATURE	
2.1.	Introduction	20
2.2.	Presenting symptoms	21
2.3.	Presenting signs	22
2.4.	Precipitating factors	23
2.5.	The facial muscles	23
2.6.	The upper extremities, shoulder girdle and neck muscles	25
2.7.	The truncal muscles	29
2.8.	The lower extremities and the pelvic girdle muscles	30
2.9.	Pseudohypertrophy of muscles	32
2.10.	Reflexes	32
2.11.	Contractures	33
2.12.	Asymmetry of muscle involvement	33
2.13.	Skeletal deformities	33
2.14.	The cardiac muscle	34
2.15.	Concomitant diseases	36
2.16.	Abortive cases	36
2.17.	The infantile form	37
2.18.	The late adult onset form	39
2.19.	Age at onset	39
2.20.	The mode of inheritance	42
2.21.	The penetrance	44
2.22.	Sex influences	45
2.23.	Linkage studies	45
2.24.	Prevalence and incidence	46
2.25.	Fitness	47
2.26.	Mutation rate	47
2.27.	Clinical course and disability	48

2.28.	Therapy	49
2.29.	Life expectancy and causes of death	50
2.30.	Biochemical studies	51
2.31.	Electromyography	54
2.32.	Muscle biopsy	57
2.33.	Summary	60

CHAPTER 3. THE FACIOSCAPULOHUMERAL SYNDROME: DIFFERENTIAL DIAGNOSIS OF FACIOSCAPULOHUMERAL DISEASE

3.1.	Introduction	63
3.2.	Scapulooperoneal muscular dystrophy	64
3.3.	Congenital myopathies	67
3.4.	Polymyositis	71
3.5.	Myopathies with abnormal mitochondria	75
3.6.	Scapulooperoneal amyotrophy with sensory disturbances (Davidenkow's syndrome)	79
3.7.	Spinal muscular atrophies	83
3.8.	Facioscapulohumeral and scapulooperoneal syndromes with cardiomyopathy	94
3.9.	Summary	101

CHAPTER 4. FACIOSCAPULOHUMERAL DISEASE: PERSONAL OBSERVATIONS

4.1.	Introduction	103
4.2.	The patients	105
4.3.	The kindreds	110
4.4.	Symptoms	128
4.5.	Precipitating factors	131
4.6.	Presenting signs	131
4.7.	The facial muscles	133
4.8.	The shoulder girdle, the pelvic girdle and the limb muscles	134
4.9.	The truncal muscles	138
4.10.	Asymmetry of muscle involvement	139
4.11.	Reflexes	142
4.12.	Muscle contractures	142
4.13.	Hypertrophy of muscle	143

4.14.	Skeletal abnormalities	144
4.15.	The cardiac muscle	144
4.16.	Concomitant diseases	145
4.17.	The age of onset	146
4.18.	Abortive cases	150
4.19.	Infantile onset and onset in early childhood	152
4.20.	The clinical course and disability	155
4.21.	Death	160
4.22.	Penetrance	160
4.23.	Sex influences	162
4.24.	Genetic heterogeneity	163
4.25.	Environmental influences	164
4.26.	Fitness	164
4.27.	Genealogical examination	165
4.28.	Prevalence	166
CHAPTER 5.	LABORATORY STUDIES	
5.1.	Introduction	168
5.2.	Serum creatine kinase activity	168
5.3.	Genetic linkage	172
5.4.	Electrophysiological studies	175
5.5.	Muscle biopsies	178
5.6.	Discussion	187
CHAPTER 6.	CASES RESEMBLING FACIOSCAPULOHUMERAL DISEASE	191
CHAPTER 7.	GENERAL DISCUSSION	195
SUMMARY		203
SAMENVATTING		207
CURRICULUM VITAE		213
ACKNOWLEDGEMENTS		214
REFERENCES		217

LIST OF ABBREVIATIONS

ATP-ase	adenosine triphosphatase
A-V	atrio-ventricular
BSAPP	brief small abundant polyphasic potentials
CK	creatine kinase
ECG	electrocardiogram
EMG	electromyogram
FSH	facioscapulohumeral
FSHD	facioscapulohumeral disease
FSHS	facioscapulohumeral syndrome
HE	haematoxilin and eosin
LD	lactic dehydrogenase
MRC	medical research council
NADH-TR	NADH-tetrazolium reductase
PAP	persistent atrial paralysis
PK	pyruvate kinase
PMA	peroneal muscular atrophy
SGOT	serum glutamic oxaloacetic transaminase
SGPT	serum glutamic pyruvic transaminase
SMA	spinal muscular atrophy
SP	scapulooperoneal
SPD	scapulooperoneal muscular dystrophy

Introduction

The purpose of this study is to discuss several aspects of facioscapulohumeral disease, also called "autosomal dominant facioscapulohumeral muscular dystrophy" or "Landouzy-Dejerine type of muscular dystrophy" or "Landouzy-Dejerine's disease". We consider this disorder well defined and recognizable, justifying the term facioscapulohumeral disease, abbreviated FSHD.

We studied the literature, as well as a personal series of 107 cases of FSHD. Chapter 1 reviews the major historical reports pertinent to the recognition of FSHD as an independent entity. Chapter 2 describes current knowledge on FSHD: a summary is presented at the end of this chapter. Chapter 3 discusses the differential diagnosis of FSHD. A great deal has been written on this subject, most of it causing more confusion than clarification. As it was considered necessary to argue why some reports were so obfuscating, this chapter has become quite lengthy: for those who feel that this subject should not claim so much attention, a summary is proffered. Chapter 4 deals with the results of the clinical examination of 107 patients with FSHD and Chapter 5 with the laboratory studies in some of these patients. The kindreds were ascertained through probands that had been studied at the "Muscular Research Center" (head Prof. Dr. J. Bethlem) of the University of Amsterdam and at the Neuromuscular Clinic (head Dr. A.R. Wintzen) of the Department of Neurology (chairman Prof. Dr. G.W. Bruyn) of the University of Leiden. The kindreds were examined as extensively as possible. In three instances family examination was incomplete or did not reveal autosomal dominant inheritance. These cases are discussed briefly in Chapter 6. In the last chapter some of our results are compared with concepts dominating in the literature.

In order to provide a framework for the discussion of this autosomal dominant disorder, we prefer to summarize FSHD as follows: the presenting complaints are mostly those of weakness of the shoulder girdle muscles. The clinical signs at the time of

presentation include weakness and atrophy of the shoulder girdle muscles with early involvement of the facial muscles in most cases. The disease subsequently spreads to the upper arm muscles, justifying the adjective facioscapulohumeral (Landouzy and Dejerine, 1884, 1885, 1886) and to the peroneal muscles. Weakness of the abdominal muscles may occur early. Pelvic girdle weakness is a fairly late sign in most cases. The muscle involvement is often asymmetrical. The intrafamilial and interfamilial expression of the disease is quite variable. The clinical course and rate of progression of the disease may also vary considerably from case to case. A large number of affected individuals may be asymptomatic (abortive cases). The age of onset may range from infancy to late adulthood. The penetrance of the gene is almost complete. There are no solid grounds to assume to existence of an autosomal recessive disorder resembling FSHD. The problem of the isolated case in which the examination of the family is negative, has no simple answer: there can be low expressivity of the gene in the ancestry, non-paternity, a mutation, or a different disease altogether. Although FSHD is considered a myopathy, both electromyography (EMG) and muscle biopsy may reveal features suggesting a neurogenic lesion.